CASR and Alzheimer disease: The results reported herein further strengthen our view22–24 that calcilytics embody a novel class of anti-AD therapeutics that effectively maintain the physiological shedding of neurotrophic and neuroprotective sAPPα by human astrocytes, as well as fully antagonizing all Aβ25–35•CaSR signalling-elicited neurotoxic effects, even in the presence of microglial proinflammatory cytokines.